Correction: Quality and reliability assessment of systemic lupus erythematosus related health information on short video platforms - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Correction: Evaluation of the Quality and Trustworthiness of Health Information on Systemic Lupus Erythematosus from Short Video Platforms

  • By

  • Lingling Gao

  • Yujie Yang

  • Yuchen Wang

  • Kunling Wang

  • Wanqing Li

  • Hongrui Wen

  • Yunan Zhang

  • Xiangfeng Li

  • Wei Bai

  • September 3, 2026

Share

Clinical Scorecard: Correction: Evaluation of the Quality and Trustworthiness of Health Information on Systemic Lupus Erythematosus from Short Video Platforms

At a Glance

CategoryDetail
ConditionSystemic Lupus Erythematosus
Key MechanismsAssessment of health information quality and reliability
Target PopulationIndividuals seeking information on systemic lupus erythematosus
Care SettingDigital health platforms

Key Highlights

  • Correction regarding authorship
  • Focus on health information quality
  • Assessment of short video platforms

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

        Risks

          Patient & Prescribing Data

          None

          None

          Clinical Best Practices

          • Ensure reliable sources for health information
          • Evaluate the trustworthiness of digital health content

          Related Resources & Content

          Original Source(s)

          Correction: Quality and reliability assessment of systemic lupus erythematosus related health information on short video platforms

          • by Lingling Gao, Yujie Yang, Yuchen Wang, Kunling Wang, Wanqing Li, Hongrui Wen, Yunan Zhang, Xiangfeng Li, Wei Bai

          • September 3, 2026

          Related Content

          Accelerated immunosenescence in SLE: current evidence and clinical translation

          Does TYK2/JAK1 Show Potential in Inflammatory Diseases?

          Investigational inhibitor was not associated with treatment-related serious adverse events and produced biomarker changes consistent with pathway inhibition in healthy volunteers.

          TNFAIP3/A20 dysfunction drives innate and sterile hyperinflammation